KR101715646B1 - INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex - Google Patents
INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex Download PDFInfo
- Publication number
- KR101715646B1 KR101715646B1 KR1020130052402A KR20130052402A KR101715646B1 KR 101715646 B1 KR101715646 B1 KR 101715646B1 KR 1020130052402 A KR1020130052402 A KR 1020130052402A KR 20130052402 A KR20130052402 A KR 20130052402A KR 101715646 B1 KR101715646 B1 KR 101715646B1
- Authority
- KR
- South Korea
- Prior art keywords
- antiviral
- virus
- extract
- group
- present
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 78
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 24
- 235000009337 Spinacia oleracea Nutrition 0.000 claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 241000219315 Spinacia Species 0.000 claims description 21
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 18
- 241000700584 Simplexvirus Species 0.000 claims description 17
- 241001529459 Enterovirus A71 Species 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 235000020710 ginseng extract Nutrition 0.000 abstract description 10
- 230000015788 innate immune response Effects 0.000 abstract description 9
- 208000035473 Communicable disease Diseases 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 230000003612 virological effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 244000300264 Spinacia oleracea Species 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 25
- 230000036039 immunity Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 230000006698 induction Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 13
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 10
- 241000709661 Enterovirus Species 0.000 description 9
- 102000003996 Interferon-beta Human genes 0.000 description 9
- 108090000467 Interferon-beta Proteins 0.000 description 9
- 229960001388 interferon-beta Drugs 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 208000019061 glycogen storage disease due to GLUT2 deficiency Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000003308 immunostimulating effect Effects 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 6
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000002073 fluorescence micrograph Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 241000709687 Coxsackievirus Species 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000000233 Melia azedarach Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000010359 Newcastle Disease Diseases 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000219784 Sophora Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000204955 Colorado tick fever virus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027201 Meningitis aseptic Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- -1 triterpene compounds Chemical class 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- DABHSVCBZNIZDT-WFJMIKGLSA-N (2r,5r)-5-(3,3-dimethyloxiran-2-yl)-3-[(3s,9r,10r,13s,14s,17r)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]oxolan-2-ol Chemical compound CC1(C)OC1[C@@H]1O[C@@H](O)C([C@@H]2[C@@]3(CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)C5CC=C4[C@@]3(C)CC2)C)C1 DABHSVCBZNIZDT-WFJMIKGLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000709734 Coxsackievirus A24 Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- DABHSVCBZNIZDT-UHFFFAOYSA-N Deacetylturraeanthin Natural products CC1(C)OC1C1OC(O)C(C2C3(CCC4C5(C)CCC(O)C(C)(C)C5CC=C4C3(C)CC2)C)C1 DABHSVCBZNIZDT-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000158723 Melia Species 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 241001098054 Pollachius pollachius Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DABHSVCBZNIZDT-JJDPDEBESA-N melianol Natural products CC1(C)O[C@H]1[C@H]1C[C@H]([C@H](O)O1)[C@@H]1CC[C@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]12C DABHSVCBZNIZDT-JJDPDEBESA-N 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 고련피 추출물을 포함하는 선천 면역 증강 및 항바이러스용 조성물, 및 고련피 추출물을, 인간을 제외한 선천 면역 증강이 필요한 동물에 투여하는 것을 포함하는 동물의 선천 면역 증강 및 항바이러스 활성 증강 방법에 관한 것이다. 본 발명에 따른 선천 면역 증강 및 항바이러스용 조성물은 항바이러스 활성 및 선천 면역 증강 효능을 나타내어, 박테리아 및 바이러스 감염성 질환의 예방 및 치료용으로 적용될 수 있고, 면역이 저하되거나 면역이 억제된 환자의 면역력 증강 및 조절을 위한 의약이나 건강기능식품, 및 동물의 항질병 강화를 목적으로 하는 선천 면역증강 및 항바이러스용 사료 등으로 광범위하게 이용될 수 있다. 또한, 본 발명에 따른 선천 면역 증강 및 항바이러스용 조성물은 독성이나 부작용을 거의 일으키지 않으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.The present invention relates to a method for enhancing innate immunity and antiviral activity of an animal, which comprises administering a composition for congenital immune enhancement and antiviral comprising a spinach extract, and a ginseng extract to an animal in need of innate immunity, . The composition for congenital immune enhancement and antiviral according to the present invention exhibits antiviral activity and innate immune enhancing effect and can be applied for prevention and treatment of bacterial and viral infectious diseases and can be applied to immunity- Medicines and health functional foods for the enhancement and regulation, and congenital immune enhancement and antiviral feeds for enhancing the anti-disease of animals. In addition, the composition for congenital immune enhancement and antiviral according to the present invention scarcely causes toxicity or side effects, so that it can be safely used for prolonged use even for prophylactic purposes.
Description
본 발명은 선천면역 증강 및 항바이러스 조성물에 관한 것으로, 더욱 상세하게는 의약, 건강기능식품 및 사료 조성물 등으로 이용될 수 있는 고련피 추출물을 포함하는 선천면역 증강 및 항바이러스 조성물에 관한 것이다.
The present invention relates to a congenital immune enhancement and antiviral composition, and more particularly, to a congenital immunostimulating and antiviral composition comprising an extract of a ginseng extract which can be used as medicines, health functional foods and feed compositions.
면역은 태어날 때부터 지니고 있는 선천 면역(innate immunity)과 후천적으로 생활하면서 적응되어 얻어지는 획득 면역(acquired immunity)으로 구분될 수 있다. 선천 면역은 일명 '자연 면역'이라고도 하며, 항원에 대해 비특이적으로 반응하고, 특별한 기억작용은 없는 것을 특징으로 한다.Immunity can be divided into innate immunity, which is born from birth, and acquired immunity, which is obtained by adapting to life. Congenital immunity is also called "natural immunity" and is characterized by nonspecific responses to antigens and no special memory effect.
생체내 선천적 방어 면역시스템 중 최근 가장 중요시되는 연구 분야는 인터페론(interferon)에 의해 유도되는 선천성 면역분야이며, 이러한 인터페론 매개 면역의 활성화는 다양한 전염병 병원체에 대한 근본적인 예방 방법이 될 수 있다. 따라서 인터페론 활성화 기전 연구 및 인터페론을 유도시킬 수 있는 면역조절제제의 개발 연구가 활발하다. 또한, 병원체의 감염에 따른 선천 면역의 방어기작의 하나로 면역 인자(염증 사이토카인)가 분비되고, 이들 인자들에 의해 염증반응이 유발되어 병원체에 대한 방어가 이루어진다. 따라서 적정한 수준의 염증반응 유도 역시 다양한 전염병 병원체에 대한 예방 및 치료 방법이 될 수 있으며, 이를 유도시킬 수 있는 면역증강제제의 개발 연구가 필요하다.Among the in vivo innate defense immune systems, the most important research field is the field of congenital immunity induced by interferon. Such activation of interferon-mediated immunity can be a fundamental preventive measure against various infectious pathogens. Therefore, studies on the interferon activation mechanism and development of immunoregulatory agents capable of inducing interferon have been actively conducted. In addition, immune factors (inflammatory cytokines) are secreted as a defense mechanism against congenital immune diseases caused by pathogenic infections, and inflammatory responses are induced by these factors to protect against pathogens. Therefore, induction of inflammatory response at an appropriate level may be a preventive and therapeutic method for various infectious disease pathogens, and development of an immunity enhancer that can induce the inflammatory response is needed.
바이러스(virus)란 라틴어로 독성물질을 의미하며, 세균여과지(0.22㎛)를 통과하는 일군의 감염형 병원성 입자를 의미한다. 바이러스는 숙주세포의 종류에 따라 박테리오 파지, 식물 바이러스, 동물 바이러스로 분류하기도 하며, 핵산의 종류에 따라 DNA 바이러스, RNA 바이러스로 분류할 수 있다. 최근 신종플루, AI 및 구제역 등 다양한 바이러스 질병이 사회적으로 큰 문제를 일으켰으며, 이에 따라 바이러스 질병의 효과적인 대책에 대한 고민이 사회적으로 큰 관심을 불러일으키고 있다.Virus means a toxic substance in Latin and refers to a group of infectious pathogenic particles that pass through bacterial filter paper (0.22 μm). Viruses can be classified as bacteriophages, plant viruses, and animal viruses according to the type of host cells. DNA viruses and RNA viruses can be classified according to the type of nucleic acid. Recently, various virus diseases such as H1N1, AI, and foot-and-mouth disease have caused a great social problem, and the concern about effective measures for viral diseases has raised a great interest in society.
현재 바이러스성 질병을 예방하기 위해서 가장 좋은 방법은 백신접종이다. 그럼에도 불구하고 바이러스에 의한 질병의 경우, 대체적으로 많은 바이러스 혈청형(아형) 생성 등에 따른 백신의 효율성 문제가 중요하게 제기되고 있다. 이러한 백신의 문제점을 보완해 줄 수 있는 바이러스 예방용 억제제의 개발 및 보급은 중요한 사항이며, 이를 위해 특히 바이러스에 대한 초기 방어시스템인 생체내 선천적 면역시스템을 자극하여 개체 동물의 면역력을 높여주는 예방제제의 발굴 및 개발은 중요한 제제 개발 방법이 될 수 있다.Currently, vaccination is the best way to prevent viral diseases. Nevertheless, in the case of diseases caused by viruses, the efficiency of vaccines due to the generation of many virus serotypes (subtypes) is important. The development and dissemination of antiviral inhibitors that can overcome the problems of these vaccines is an important issue. For this purpose, a preventive agent that enhances immunity of an individual animal by stimulating the in vivo innate immune system, Can be an important method of drug development.
인플루엔자 바이러스의 증식을 억제하는 대표적인 항바이러스 제제로는 아만타딘(amantadine)과 리만타딘(rimantadine)이 있으나, 이들 두 가지 항바이러스 제제들은 혈청형 A형 인플루엔자 바이러스에만 효과적이며, M2 단백질이 없는 혈청형 B형 인플루엔자 바이러스에는 효과가 없는 것으로 확인되었다. 또한 아만타딘과 리만타딘은 사용 시 인플루엔자 바이러스 M2 단백질의 이온채널기능에 영향을 미치지 못하는 변이 바이러스의 출현이 매우 쉽게 일어나는 단점이 있는 것으로 확인되고 있다. 이러한 단점을 보완하기 위하여 16종의 모든 혈청형 A형 인플루엔자 바이러스와 혈청형 B형 인플루엔자 바이러스에 효과적인 항바이러스 제제로 자나미비르(zanamivir)와 오셀타미비르(oseltamivir)가 개발되었다. 그러나 자나미비르는 흡입 및 정맥 투여해야 하는 단점이 있으며, 오셀타미비르는 경구투여가 가능하나 최근 내성 바이러스의 출현 보고와 경구투여 시 구토와 현기증 등의 부작용이 있어 단점으로 지적되고 있다.Amantadine and rimantadine are two typical antiviral agents that inhibit the proliferation of influenza virus. However, these two antiviral agents are effective only for the serotype A influenza virus and the serotype B It has been confirmed that it is not effective against influenza virus. In addition, amantadine and rimantadine have been found to have a disadvantage in that the mutant virus, which does not affect the ion channel function of the influenza virus M2 protein, appears very easily. To overcome this drawback, zanamivir and oseltamivir have been developed as antiviral agents effective against all 16 serotype A influenza viruses and serotype B influenza viruses. However, there is a disadvantage that Zanamivir should be administered by inhalation and intravenous injection. Ocelaminivir can be administered orally, but it is pointed out as a disadvantage due to recent reports of the emergence of resistant virus and side effects such as vomiting and dizziness when administered orally.
또한, 뉴캐슬병 바이러스에 대한 백신은 크게 생독 백신과 사독 백신으로 구분되는데, 가장 널리 이용되어온 대표적인 뉴캐슬병 생독 백신주인 B1주와 La Sota주(Clone주 포함)는 백신 접종 반응을 유발하는 것으로 알려져 있으며, 전 세계적으로 사용되고 있는 뉴캐슬병 사독 백신인 다가혼합 사독 오일 백신은 1회 백신 접종으로 3종 이상의 질병이 동시에 예방될 수 있으나, 산란계 농장의 경우 면역력 저하로 인한 뉴캐슬병 발생 피해 사례가 늘어나고 있다.In addition, vaccines against Newcastle Disease virus are classified into virulence vaccine and Sadox vaccine. It is known that the most widely used Newcastle disease virulence vaccine, B1 strain and La Sota strain (including Clone strain) The multivitamins combined vaccine oil vaccine, a Newcastle Disease vaccine that is used globally, can prevent three or more diseases at the same time by a single vaccination. However, in the case of laying hens farms, cases of Newcastle disease caused by immunity reduction are increasing.
또한, 수포성 구내염 바이러스(Vesicular stomatitis virus)의 주된 통제 방법은, 질병의 완전 치료가 불가능하기 때문에, 구제역과 마찬가지로 예방 및 차단 방역과 발생 지역 내 감수성 가축의 박멸이 최선의 방법이다.In addition, the main control method of vesicular stomatitis virus is the complete treatment of the disease, so as with foot-and-mouth disease, prevention and blocking prevention and eradication of susceptible domestic livestock are the best methods.
또한, RNA 바이러스 가운데에서도 비교적 크기가 작은 바이러스들이 있다. 이들은 작다는 뜻의 'pico'라는 말과 RNA를 합쳐 피코나바이러스라고 부르며, 여기에 속한 바이러스들을 통틀어 피코나바이러스과 (Piconaviridae)라고 부른다. 피코나바이러스과에 속하는 엔테로바이러스는 무균성 수막염, 수족구병, 포진성 구협염, 확장성 심근염, 급성 출열성 결막염 등의 다양한 임상증상을 일으키는 약 70가지 혈청형을 포함하고 있으며, 폴리오바이러스 (Poliovirus), 콕사키바이러스(Cossackievirus) 및 에코바이러스 (Echovirus)와 기타 엔테로바이러스로 분류된다. 엔테로바이러스는 바이러스 입자의 직경이 20~30 나노미터 정도이며 외가닥의 RNA를 유전자로 가진다. 대부분이 등뼈동물의 소화기관을 비롯하여 호흡기관 및 중추신경계에까지 감염되지만 뚜렷한 병징을 나타내지 않는 경우가 많다. 콕사키바이러스 (Coxsackievirus, CXV)는 피코나바이러스과에 속하는 사람 엔테로바이러스(human enterovirus)로서, 크게 A형 (A type)과 B형 (B type)으로구분된다(Pallansch MA and Roos RP, Fields Virology, 4th edi, pp723-775, 2001).There are also relatively small viruses among RNA viruses. They combine the word "pico", which means small, and RNA, called picornavirus, which are called piconaviridae. The enteroviruses belonging to the picornaviridae group contain about 70 serotypes which cause various clinical symptoms such as aseptic meningitis, hand hygiene, herpetic myelitis, acute exacerbation of conjunctivitis and poliovirus. , Cossackievirus and Echovirus, and other enteroviruses. The enteroviruses are 20 to 30 nanometers in diameter, and have RNAs in their outer strands as genes. Most are infected with the digestive organs of the vertebrate, the respiratory tract and the central nervous system, but often do not exhibit distinct symptoms. Coxsackievirus (CXV) is a human enterovirus belonging to the picornaviridae. It is divided into A type and B type (Pallansch MA and Roos RP, Fields Virology, 4th ed., Pp. 723-775, 2001).
또한 최근 세계 곳곳에서 고위험성 엔테로바이러스 및 변종 바이러스 (엔테로바이러스 71형, 콕사키바이러스 A24 변이주)가 새롭게 발견되어 유행되고 있어 이를 조기에 탐지하기 위한 국가 간 공동감시체계 구축이 요구되고 있다. 실제로 국내에서 2000년 엔테로바이러스 71형, 무균성 수막염이 크게 유행한 2002년에는 에코바이러스 13형, 전국적으로 급성출혈성 결막염이 폭발적으로 유행했던 2002년과 2003년에는 콕사키바이러스 A24형 변이주가 유행했음을 확인하고 이에대한 대국민 홍보를 실시한 바 있다.Recently, high-risk enteroviruses and variant viruses (enterovirus type 71, coxsackievirus A24 mutant strain) have been newly discovered and popular in many parts of the world and it is required to establish a common monitoring system for detecting these viruses early. In fact, in 2002 and 2003, the A24 variant of the coxsackievirus was prevalent in Korea in 2002 when echovirus type 13 was the most prevalent type of enterovirus type 71, aseptic meningitis in 2000, and in acute hemorrhagic conjunctivitis nationwide And publicity of the public was conducted.
콕사키바이러스를 포함하는 엔테로바이러스는 척추동물의 소화기관을 비롯하여 호흡기관 및 중추신경계에까지 감염되어다양한 임상증상을 유발하기 때문에 국가 차원의 대책 마련이 시급히 요구되고 있으나 바이러스의 종류와 혈청형이 매우다양하여 효과적인 상용화 백신이나 치료제가 개발되어 있지 못한 실정이다.Since enteroviruses including Coxsackie virus are infected to the respiratory organs and central nervous system including vertebrate animal digestive organs and cause various clinical symptoms, national measures are urgently required, but the types and serotypes of viruses are very various Thus, effective commercialized vaccines and therapeutic agents have not been developed.
헤르페스 심플렉스 바이러스(Herpes Simplex Virus; 이하 HSV)는 헤르페스 바이러스 속에 속하는 DNA 바이러스로서 약 175nm의 크기를 가지는 비교적 큰 바이러스이며, 인간에게 널리 퍼져 있는 감염체이다. 단순포진 감염은 HSV 1형(이하, 'HSV-1'라 함) 및 HSV 2형(이하, 'HSV-2'라 함)의 감염으로써, 점막이나 피부를 침범하는 급성 수포성질환이며 아토피가 있는 사람에게서 흔히 볼 수 있는 감염질환이다. HSV-1은 주로 입과 안구 주위에, HSV-2는 성기주위에 수포를 형성시킨다. 이러한 HSV의 감염은 면역기능이 저하되어 있는 환자들에게는 그 정도가 심하게 진행되며 경부암의 원인으로도 작용하는 것으로 보고되어 있다(Melnick, J. L., Adam, E. and Rawls, W., Concer, 34, 1355-1385(1974); Cabral, G. A., Fry, D., Marciono-Carbral, F., Lumplcin, C., Mercer, L. and Goplerud, D., Am. J. Obstet. Gynecol., 145, 79-86(1983)). 또한, 신생아나 태아의 경우에는 스스로 HSV 항체를 생성하지 못할 뿐 아니라 모체의 항체가 태아에게 넘어가지 못하기 때문에, 일단 감염되면 대부분 치명적인 결과를 초래하게 된다고 알려져 있다. 현재, HSV-1에 의한 안구질환의 경우는 미국내에서만 일년에 약 50 만명의 환자가 발생하며 이중 1000 명이상은 안구 이식수술을 받고 있는 것으로 알려져 있다(Nesburn, A. B., Vision Research: national plan 1983-1987, vol. II, part III, The C. V. Mosby Co., St. Louis. (1983); Smith, R. E. et al., Arch. Ophthalmol 98, 1226(1980)). HSV-2의 경우 약 95%는 활동성 병변이 있는 상대방과의 성적 접촉을 통해 감염되는 것으로 알려져 있는데, 미국성인중 약 20∼30%가 HSV-2에 감염되어 있으며, 이중 20 내지 50%는 재발성 성기포진을 갖는 것으로 보고되어 있다(Johnson R. E. et al., N. Engl. J. Med., 321, 7(1989); Breinig M. K. et al., J. Infect. Dis., 162, 299(1990); Langenberg A. et al., Ann. Intern. Med., 110, 882(1989); Koutsky L. A. et al., N. Engl. J. Med., 326, 1533(1992)).Herpes simplex virus (hereinafter referred to as HSV) is a relatively large virus having a size of about 175 nm, which is a DNA virus belonging to the genus Herpesvirus, and is an infectious agent widely spread to humans. Herpes simplex infection is an infectious disease of HSV type 1 (hereinafter referred to as 'HSV-1') and HSV type 2 (hereinafter referred to as 'HSV-2'), It is a common infectious disease in people with HSV-1 mainly forms around the mouth and eye, and HSV-2 forms blisters around the penis. In addition, it has been reported that HSV infection is a serious cause of cervical cancer in immunocompromised patients (Melnick, JL, Adam, E. and Rawls, W., Concer, 145, 79 (1974) Cabral, GA, Fry, D., Marciono-Carbral, F., Lumplcin, C., Mercer, L. and Goplerud, D., Am. J. Obstet., Gynecol. -86 (1983)). In addition, it is known that newborns and fetuses can not produce HSV antibodies themselves, and that antibodies to maternal antibodies can not be passed on to the fetus. It is known that HSV-1-associated ocular disease occurs in the United States alone in about 500,000 patients a year, of which more than 1,000 are undergoing ocular surgery (Nesburn, AB, Vision Research: national plan 1983 (1983); Smith, RE et al., Arch. Ophthalmol 98, 1226 (1980)). Approximately 95% of HSV-2 infections are known to be transmitted through sexual contact with opponents with active lesions. About 20-30% of US adults are infected with HSV-2, of which 20-50% 162, 299 (1990), which is incorporated herein by reference in its entirety, and has been reported to have sexual dysplasia (Johnson RE et al., N. Engl. J. Med., 321, Koutsky LA et al., N. Engl. J. Med., 326, 1533 (1992)).
HSV는 초기 감염 후에 피부나 점막 표피세포에서 복제를 시작하여 신경조직을 따라 이동한 후, 전 생애에 걸쳐 척추신경절에 잠복하고 있다가 면역기능이 저하될 경우 재활성화 되어 감염부위로부터 여러가지 질환을 발생시키는 것으로 알려져 있다(Corey L., Sexually transmitted disease, 2nd ed., New York: McGraw Hill, (1990)). HSV에 의한 감염질환에 대한 치료제로는 뉴클레오사이드(nucleoside) 유도체인 아시클로비르(Acyclovir)가 초기감염에 매우 효과적인 것으로 알려져 있으나(Bryson, Y. J. et al., N. Engl. J. Med., 308, 916(1983); Mertz G. J. et al., Am. Med.Assoc., 252, 1147(1984)), 이 약제의 효과를 유지하기 위해서는 약제를 계속적으로 투여해야 하며, 투여가 중단될경우 HSV에 의한 감염질환이 재발하는 것으로 알려져 있다(Mindel A. et al., Lancet i: 926-928(1988); Straus S.E. et al., N. Engl. J. Med., 310, 1545(1984)). 또한 HSV의 최초 감염에 대한 치료 후 재발하는 경우에는 치사율이 높다고 보고되어 있다(Nahmias, A. J. and Coleman, R. M., Immunobiology of Herpes Simplex Virus Infection CRC Press, Boca Raton, PP. 92-102(1984)).After HSV infection, HSV begins to replicate in skin or mucosal epidermal cells and travels along the nervous system. After HSV infection, the spinal ganglion is latent throughout the entire life span and reactivated when the immune function deteriorates. (Corey L., Sexually transmitted disease, 2nd ed., New York: McGraw Hill, (1990)). Acyclovir, a nucleoside derivative, is known to be highly effective for early infections (Bryson, YJ et al., N. Engl. J. Med. 308, 916 (1983); Mertz GJ et al., Am. Med. Assoc., 252, 1147 (1984)). In order to maintain the efficacy of this drug, 310, 1545 (1984)) have been known to recur infectious diseases caused by infection (Mindel A. et al., Lancet i: 926-928 (1988); Straus SE et al., N. Engl. J. Med. . It has also been reported that the recurrence after treatment for the first infection of HSV has a high mortality (Nahmias, A.J. and Coleman, R.M., Immunobiology of Herpes Simplex Virus Infection CRC Press, Boca Raton, pp. 92-102 (1984)).
지금까지 이러한 HSV의 감염을 예방하기 위한 백신이 개발되어 왔으나, 바이러스 자체를 약화시켜 사용하는 생백신(live attenuated vaccine)은 HSV의 게놈이 종양발생(oncogenesis)에 직접 관여한다는 사실이 밝혀짐으로 인해서 그사용이 금지되어 왔다(Cappel, R., Sprecher, S., De Cuyper, F. and De Braekeleer, J., J. Med. Virol., 16, 137-145(1985)).Although a vaccine has been developed to prevent the infection of HSV, live attenuated vaccine, which weakens the virus itself, has been shown to be directly involved in the oncogenesis of the HSV genome. (Cappel, R., Sprecher, S., De Cuyper, F. and De Braekeleer, J., J. Med. Virol., 16, 137-145 (1985)).
이러한 상황하에서, 최근 해외 및 국내에서 기존의 항바이러스 제제의 단점을 극복하고자 많은 노력들이 이루어지고 있으며, 그 노력 중의 하나로 국내에서는 생약 추출물 및 식물 추출물을 대상으로 항바이러스 효능에 대한 연구가 활발히 진행중이다.Under these circumstances, many efforts have recently been made to overcome the disadvantages of existing antiviral agents both in foreign countries and domestic ones. As one of the efforts, researches on antiviral efficacy of herbal medicine extracts and plant extracts are actively underway in Korea .
한편, 고련피(Meliae Cortex)는 연과(멀구슬나무과; meliaceae)에 속한 낙엽교목인 고련나무(Melia azedarachvar. Japonica Makino., 약동 Melia azedarach L. 천동 Melia toosendan Sieb. er Zucc.) 및 멀구슬나무(Melia acedarach Linne var. japonica Makino)의 수피 또는 근피를 건조한 것으로 청열(淸熱), 조습(燥濕),살충(殺蟲)효과가 있어 회충(蛔蟲), 요충(蟯蟲), 풍진(風疹), 개선(疥癬) 등의 증상을 치료하는 약으로 이용된다. 일반적으로 고련피는 맛이 쓰고 특이한 냄새가 있어 통칭 소태나무라고도 불린다. 고련피의 쓴맛은 알카로이드계 물질을 포함하고 있기 때문이며, 또한 마르고신(Margosin)등의 수지류를 함유하고 있어 건위제, 진경등 동양의약에서 다양한 용도의 약제로 사용되고 있다. On the other hand, Meliae Cortex is a deciduous tree (Melia azedarachvar. Japonica Makino., Melia azedarach L. Melodicus Melia toosendan Sieb. Er Zucc.) Belonging to the myrtle (Meliaceae) It is dried with bark or flesh of wood (Melia acedarach Linne var. Japonica Makino), and has the effect of cleansing, drying, insecticide, Rubella) and improvement (scabies) are used to treat symptoms such as. In general, the taste is bloomed and has a peculiar smell, so it is also known as the common tree. The bitter taste of goryeon bloom is due to its alkaloids, and it also contains margins such as Margosin, which are used as medicines for oriental medicines such as noodles and shiniku.
상기 식물은 높이 15-20 m의 낙엽성 교목으로 동아시아나 호주등지에 분포되어 있으며, 우리나라에서는 주로 남부지방이나 제주도에서 자생하고 있다. 개화기는 4-5월이고 결실기는 10-11월이다. 고련피에는 고미를 나타내는 여러 종류의 트리테르펜계 성분 및 락톤 화합물이 함유되어 있으며, 기타 시토스테롤(sitosterol), 카테친(catechin) 및 플라보노이드(flavonoids) 등도 함유되어 있는 것으로 알려져 있다. 고련피 나무열매(고련자)의 과육과 과피에도 멜리아논(melianone), 멜리아놀(melianol)과 같은 고미 성분이 들어 있으며, 기타 불포화지방산이 다량 함유되어 있다.These plants are deciduous trees with a height of 15-20 m and are distributed in East Asia and Australia. In Korea, they are mainly grown in southern part and Jeju island. Flowering period is from April to May and fertile period is from October to November. Goryeonpipes contain various kinds of triterpene compounds and lactone compounds, which are known as gummy, and it is also known to contain other sitosterol, catechin and flavonoids. The pulp and peel of Goryeongbok (Goryeonji) contains melanone, melianol, and other unsaturated fatty acids.
종래의 고련피에 대한 연구결과들을 분류하면 알레르기질환의 예방 및 췌장암 치료용, 스트레스성질환 등의 보고가 있으나 면역증간 또는 항바이러스 효과에 대한 효과는 찾아볼 수 없다. There are reports of prevention of allergic diseases, treatment of pancreatic cancer, and stress-related diseases, but no effect on immune-stimulating or antiviral effects can be found.
이에, 기존의 항바이러스 제제의 단점을 극복하여 독성 및 부작용이 거의 없이 우수한 면역 증강 효과 및 항바이러스 활성을 발휘할 수 있는 고련피 추출물을 이용한 조성물에 대한 요구가 여전히 존재하는 실정이다.
Accordingly, there is still a need for a composition using a ginseng extract which can overcome the disadvantages of existing antiviral agents and exhibit excellent immunity enhancement and antiviral activity with little toxicity and side effects.
본 발명자들은 고련피의 추출물이 선천 면역의 주요 세포인 대식 세포를 활성화시켜 다양한 바이러스의 증식을 억제시킬 수 있음을 확인하여 본 발명을 완성하였다. 본 발명은 독성 및 부작용이 거의 없어 장기간 안정성을 확보하면서, 각종 바이러스 또는 세균 감염성 질병의 예방 및 치료, 약학 조성물, 건강기능식품 또는 가축 사료 조성물 등에 효과적으로 이용될 수 있는 고련피 추출물을 포함하는 면역 증강 및 항바이러스 조성물 및 동물의 면역 증강 및 항바이러스 활성 증강 방법을 제공하는 것을 그 목적으로 한다.
The inventors of the present invention completed the present invention by confirming that the extract of Orthoptera can activate macrophages which are the main cells of innate immunity and inhibit the proliferation of various viruses. The present invention relates to a composition for preventing or treating various viral or bacterial infectious diseases while securing stability for a long period of time with little toxicity and side effects, and for improving immunity including antimicrobial extracts which can be effectively used for pharmaceutical compositions, And an object of the present invention is to provide an antiviral composition and a method for enhancing immunity and antiviral activity of an animal.
상기 과제를 해결하기 위한 본 발명의 일 측면은 고련피 추출물을 포함하는 면역 증강 및 항바이러스용 약학 조성물을 제공한다.According to an aspect of the present invention, there is provided a pharmaceutical composition for immunostimulating and antivirals comprising an extract of Glycyrrhizae extract.
또한, 본 발명의 다른 일 측면은 고련피 추출물을 포함하는 면역 증강 및 항바이러스용 건강기능식품을 제공한다.In addition, another aspect of the present invention provides a health functional food for immunity enhancement and antiviral treatment, which comprises an extract of Glycyrrhizae extract.
또한, 본 발명의 또 다른 일 측면은 고련피 추출물을 포함하는 면역 증강 및 항바이러스용 사료 조성물을 제공한다.Yet another aspect of the present invention provides an immunostimulating and antiviral feed composition comprising a spinach extract.
또한, 본 발명의 또 다른 일 측면은 고련피 추출물을, 인간을 제외한 면역 증강이 필요한 동물에 투여하는 것을 포함하는 동물의 면역 증강 및 항바이러스 활성 증강을 제공한다.Still another aspect of the present invention provides an animal having immunity enhancement and antiviral activity enhancement, which comprises administering the extract to a mammal in need thereof.
본 발명에서 상기 고련피 추출물은 물, 탄소수 1 내지 4의 저급알콜 및 이들의 혼합용매로 구성되는 군으로부터 선택되는 용매, 바람직하게는 메탄올, 에탄올, 또는 부탄올로 추출한 것을 포함한다. 또한 본 발명에서, 상기 추출물에는 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조문, 또는 조정제물 또는 정제물 중 어느 하나도 포함하는 것으로 한다.In the present invention, the spinach extract includes those extracted with a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixed solvents thereof, preferably methanol, ethanol, or butanol. In addition, in the present invention, the extract includes any one of a dry extract obtained by drying an extract obtained by an extraction treatment, a diluted or concentrated liquid of an extract, an extract, or a controlled preparation or a purified product.
본 발명에서 “항바이러스”에는 예를 들어, 인플루엔자, 조류 인플루엔자, 뉴캐슬바이러스, 수포성 구내염 바이러스(Vesicular stomatitis virus), 콕사키바이러스(Cossackievirus), 수족구바이러스(Enterovirus-71), 헤르페스 심플렉스 바이러스(Herpes Simplex Virus), 구제역바이러스(Foot and mouth disease, FMD), 콜로라도참진드기열바이러스, 레오바이러스, 인간면역 결핍 바이러스, 및 간염바이러스 B형 C형, 돼지열병바이러스, 소바이러스성 설사병(Bovine Viral Diarrhea Virus), 돼지생식기호흡기증후군(.Porcine reproductive and respiratory syndrome virus), 돼지오제스키병, 로타바이러스, 파보바이러스, 돼지유행성설사(Porcine epidemic diarrhea virus)등에 적용될 수 있으나 이제 제한되지 않는다.
The term "antiviral" in the present invention includes, for example, influenza, avian influenza, Newcastle virus, Vesicular stomatitis virus, Cossackievirus, Enterovirus-71, Herpes simplex virus Herpes Simplex Virus, Foot and Mouth Disease (FMD), Colorado tick fever virus, Leovirus, Human Immunodeficiency Virus, and Hepatitis Virus Type B Type C, Pig Fever, Bovine Viral Diarrhea Virus, porcine reproductive and respiratory syndrome virus, porcine Ozski disease, rotavirus, parvovirus, porcine epidemic diarrhea virus, and the like.
본 발명에 따르면 우수한 면역 증강 효능을 발휘하는 고련피 추출물을 이용함으로써 각종 바이러스 및 세균 감염성 질병의 예방 및 치료에 효과적으로 적용될 수 있으며, 면역력 증진에 기여할 수 있다.According to the present invention, it is possible to effectively apply to the prevention and treatment of various viruses and bacterial infectious diseases by using the extracts of Glycyrrhiza epidermidis showing excellent immunity enhancing effect, and can contribute to the enhancement of immunity.
또한, 본 발명에 따른 고련피 추출물을 포함하는 면역 증강 및 항바이러스용 조성물은 독성이나 부작용을 거의 일으키지 않으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.In addition, the composition for immunostimulating and antivirally containing the extracts of the present invention hardly causes toxicity or side effects, so that it can be safely used for long-term administration for preventive purposes.
따라서, 본 발명에 따른 조성물은 박테리아 및 바이러스 감염성 질환의 예방 및 치료용으로 적용될 수 있고, 면역이 저하되거나 면역이 억제된 환자의 면역력 증강 및 조절을 위한 약학 조성물이나 건강기능식품, 및 동물의 항질병 강화를 목적으로 하는 면역증강용 사료 조성물 등으로 광범위하게 이용될 수 있다.Therefore, the composition according to the present invention can be applied for the prevention and treatment of bacterial and viral infectious diseases, and can be applied to pharmaceutical compositions and health functional foods for immunity enhancement and control of immunocompromised or immunosuppressed patients, An animal feed composition for immunity enhancement aimed at enhancing disease, and the like.
또한, 본 발명에 따르면 고련피 추출물을 면역 증강에 필요한 동물에 투여함으로써 동물의 면역을 효과적으로 안전하게 증강시킬 수 있다.
In addition, according to the present invention, the immunization of an animal can be safely and safely enhanced by administering the extract of the present invention to an animal necessary for immunity enhancement.
도 1은 본 발명에 실시예에 따른 고련피 추출물의 PR8-gfp(Swine influenza virus)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 2는 본 발명의 실시예에 따른 고련피 추출물의 VSV-gfp(Vesicular stomatitis virus)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 3은 본 발명의 실시예에 따른 고련피 추출물의 NDV-gfp(Newcastle disease virus)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 4는 본 발명의 실시예에 따른 고련피 추출물의 상피세포(Epitherial cell)에서 VSV-gfp(Vesicular stomatitis virus)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 5는 본 발명의 실시예에 따른 고련피 추출물의 H3-gfp(콕사키바이러스)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 6는 본 발명의 실시예에 따른 고련피 추출물의 HSV-gfp(헤르페스바이러스)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 7는 본 발명의 실시예에 따른 고련피 추출물의 EV-71(엔테로바이러스)에 대한 항바이러스 활성 실험결과를 나타낸다.
도 8은 본 발명의 실시예에 따른 고련피 추출물에 의한 인터페론-β 분비 유도 실험결과를 나타낸다.
도 9은 본 발명의 실시예에 따른 고련피 추출물에 의한 전염증성 사이토카인 유도 실험결과를 나타낸다.FIG. 1 shows the results of an antiviral activity test on PR8-gfp (Swine influenza virus) of a spinach extract according to an embodiment of the present invention.
FIG. 2 shows the results of the antiviral activity test for VSV-gfp (Vesicular stomatitis virus) of the extract of the hardy perennial plant according to the embodiment of the present invention.
FIG. 3 shows the results of an antiviral activity test for NDV-gfp (Newcastle disease virus) of a hardy bark extract according to an embodiment of the present invention.
FIG. 4 shows the results of an antiviral activity test for VSV-gfp (Vesicular stomatitis virus) in epitherial cells of a root extract of the present invention according to an embodiment of the present invention.
FIG. 5 shows the results of an antiviral activity test for H3-gfp (cocksuck virus) of a spinach extract according to an embodiment of the present invention.
6 shows the results of an antiviral activity test on HSV-gfp (herpes virus) of a hardy bark extract according to an embodiment of the present invention.
FIG. 7 shows the results of an antiviral activity test on EV-71 (enterovirus) of a hardy extract according to an embodiment of the present invention.
FIG. 8 shows the results of induction of interferon-beta secretion by the extract of Alaska pollack according to an embodiment of the present invention.
FIG. 9 shows the results of induction of proinflammatory cytokines by the extract of the muscovia according to the embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 본 발명의 기술적 사상을 용이하게 실시할 수 있을 정도로 상세히 설명하기 위하여, 본 발명의 바람직한 실시예를 설명하기로 한다.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명은 선천 면역의 주요 세포인 대식 세포를 활성화시켜 다양한 바이러스의 증식을 억제시킬 수 있는 고련피 추출물을 이용함으로써 면역 증강 효과를 나타내는 것을 특징으로 한다.The present invention is characterized in that it exhibits an immunostimulating effect by using a goryeo extract which can activate macrophages which are major cells of innate immunity and inhibit the multiplication of various viruses.
본 발명에 이용되는 고련피 추출물은 일반적으로 천연물 추출에 사용되는 다양한 용매를 이용한 추출에 의하여 형성될 수 있으며, 예를 들어, 열수 추출, 알코올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성될 수 있다.The extracts of platycodon used in the present invention can be generally formed by extraction using various solvents used for extracting natural products, for example, by one or more methods selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction .
일 실시예에서, 고련피 추출물은, 증류수를 첨가하는 단계; 20~130℃, 바람직하게는 약 105℃의 온도에서 30~480분 동안, 바람직하게는 약 150분 동안 열수 추출하는 단계; 및 여과하는 단계를 거쳐 형성될 수 있다.In one embodiment, the spinach extract comprises the steps of adding distilled water; Hydrothermal extraction at a temperature of 20 to 130 캜, preferably about 105 캜, for 30 to 480 minutes, preferably about 150 minutes; And filtering.
고련피 추출물은 각종 바이러스, 예를 들면 인플루엔자 바이러스, 뉴캐슬병 바이러스, 수포성 구내염 바이러스, 콕사키바이러스, 헤르페스바이러스, 엔테로바이러스71형 등에 대하여 우수한 항바이러스 활성을 나타내고, 면역 인자 유도능을 강하게 나타내며, 개체의 선천 면역을 증가시켜 바이러스의 감염 및 증식을 억제하는 효과를 발휘한다.The extract has a superior antiviral activity against various viruses such as influenza virus, Newcastle disease virus, vesicular stomatitis virus, cocksuck virus, herpes virus, enterovirus type 71, etc., To increase the innate immunity of the virus to infect and proliferate the effect is suppressed.
또한, 고련피 추출물은 세포 독성이나 부작용을 거의 나타내지 않으므로 장기간 복용시에도 안심하고 사용할 수 있다.In addition, since the extract of Sophora cordata shows little cytotoxicity or side effects, it can be used safely even when taken for a long time.
본 발명에 있어서는 이와 같은 효능을 발휘하는 고련피 추출물을 포함하는 면역 증강 및 항바이러스용 약학 조성물, 선천 면역 증강 및 항바이러스용 건강기능식품 또는 면역 증강 및 항바이러스용 사료 조성물 등에 적용할 수 있다.The present invention can be applied to a pharmaceutical composition for immune enhancement and antiviral activity, a health functional food for immunity enhancement and antivirus, a feed composition for immunity enhancement and antivirus and the like,
본 발명의 일 측면은 고련피 추출물을 포함하는 선천 면역 증강 및 항바이러스용 약학 조성물에 관한 것이다.One aspect of the present invention relates to a concomitant immunoconjugate and antiviral pharmaceutical composition comprising a spinach extract.
일 실시예에서, 본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 약학적으로 허용가능한 담체, 부형제 또는 희석제를 더 포함한다.In one embodiment, the pharmaceutical compositions for congenital immune enhancement and antiviral of the present invention further comprise a pharmaceutically acceptable carrier, excipient or diluent.
본 발명에 이용될 수 있는 약학적으로 허용가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 특히 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The pharmaceutically acceptable carrier, excipient or diluent which can be used in the present invention is not particularly limited so long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, Flavoring agents, fragrances, preservatives, and the like.
약학적으로 허용가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of pharmaceutically acceptable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium carbonate, calcium Methylcellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable Ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.
본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁액, 에멀젼, 시럽제, 에어로졸, 외용제, 좌제 및 주사제로 이루어진 군으로부터 선택되는 형태일 수 있다.The pharmaceutical composition for congenital immune enhancement and antiviral of the present invention may be in the form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and injections.
약학 조성물의 제제화 방법은 기술분야에 공지된 통상의 방법에 따라 수행될 수 있으며, 특히 제한되지 않는다.The preparation method of the pharmaceutical composition may be carried out according to a conventional method known in the art, and is not particularly limited.
본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 경구 또는 비경구 투여될 수 있으며, 투여량은 투여 대상의 연령, 성별, 체중, 상태, 질병의 정도, 약물의 형태, 투여 경로 및 기간에 따라 적절히 선택될 수 있으나, 일반적으로 약 5~500㎎/㎏, 바람직하게는 약 100~250㎎/㎏을 1일 1~3회 투여할 수 있다.The pharmaceutical composition for congenital immune enhancement and antiviral use of the present invention can be administered orally or parenterally. The dosage may be adjusted depending on the age, sex, weight, condition, degree of disease, drug form, May be appropriately selected, but generally about 5 to 500 mg / kg, preferably about 100 to 250 mg / kg, can be administered one to three times a day.
본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물의 제제화 방법, 투여량, 투여 경로, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다.It will be apparent to those skilled in the art that the method of administration, dosage, route of administration, constituents, etc. of the pharmaceutical composition for congenital immune enhancement and antiviral of the present invention can be suitably selected from conventional techniques known in the art.
본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 박테리아 감염성 질병 또는 바이러스 감염성 질병의 예방 및 치료에 이용될 수 있다.The pharmaceutical composition for congenital immune enhancement and antiviral of the present invention can be used for the prevention and treatment of bacterial infectious diseases or viral infectious diseases.
특히, 본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 독성이나 부작용을 거의 갖지 않는 고련피 추출물을 유효성분으로 함유하므로, 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.In particular, the pharmaceutical composition for congenital immune enhancement and antiviral of the present invention contains an extract of Ganoderma lucidum having almost no toxicity or side effects as an active ingredient, so that it can be safely used even for prolonged use for preventive purpose.
일 실시예에서, 본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 유효 성분으로 고련피 추출물 외에 다른 약학적 활성 성분을 함께 포함하거나, 또는 다른 유효 성분을 포함하는 약학 조성물과 혼합되어 이용될 수 있다.In one embodiment, the pharmaceutical composition for congenital immune enhancement and antiviral use according to the present invention may be used in combination with a pharmacologically active ingredient other than ginseng extract as an active ingredient, or in combination with a pharmaceutical composition containing another active ingredient have.
예를 들어, 본 발명의 선천 면역 증강 및 항바이러스용 약학 조성물은 암, 특히 전립선, 결장, 폐, 유방, 난소, 두경부, 외음부, 방광 및 뇌암, 신경교종뿐 아니라 비전염성 만성 질병의 예방 또는 치료용 약학 조성물, 인플루엔자, 조류 인플루엔자, 뉴캐슬바이러스, 수포성 구내염 바이러스(Vesicular stomatitis virus), 콕사키바이러스(Cossackievirus), 수족구바이러스(Enterovirus-71), 헤르페스 심플렉스 바이러스(Herpes Simplex Virus), 구제역바이러스(Foot and mouth disease, FMD), 콜로라도참진드기열바이러스, 레오바이러스, 인간면역 결핍 바이러스, 및 간염바이러스 B형 C형, 돼지열병바이러스, 소바이러스성 설사병(Bovine Viral Diarrhea Virus), 돼지생식기호흡기증후군(.Porcine reproductive and respiratory syndrome virus), 돼지오제스키병, 로타바이러스, 파보바이러스, 돼지유행성설사(Porcine epidemic diarrhea virus)등의 예방 또는 치료용 약학 조성물, 또는 자가면역 질병의 치료용 약학 조성물 등과 함께 사용될 수 있다.For example, the pharmaceutical composition for congenital immune enhancement and antiviral of the present invention can be used for preventing or treating cancer, particularly prostate, colon, lung, breast, ovary, head and neck, vulva, bladder, The present invention relates to a pharmaceutical composition for the treatment of influenza, avian influenza, avian influenza, Newcastle virus, Vesicular stomatitis virus, Cossackievirus, Enterovirus-71, Herpes Simplex virus, Foot and mouth disease (FMD), Colorado tick fever virus, reovirus, human immunodeficiency virus, and hepatitis B virus type C, swine fever virus, bovine viral diarrhea virus, porcine respiratory syndrome .Porcine reproductive and respiratory syndrome virus, porcine Ozeki disease, rotavirus, parvovirus, porcine ep idemic diarrhea virus), or a pharmaceutical composition for the treatment of autoimmune diseases, and the like.
본 발명의 다른 일 측면은 고련피 추출물을 포함하는 선천 면역 증강 및 항바이러스용 건강기능식품에 관한 것이다.Another aspect of the present invention relates to a health functional food for congenital immunity enhancement and antiviral treatment comprising an extract of Sophora edulis.
일 실시예에서, 본 발명의 선천 면역 증강 및 항바이러스용 건강기능식품은 식품학적으로 허용가능한 식품 보조 첨가제를 더 포함한다.In one embodiment, the congenital immunomodulating and antiviral health functional food of the present invention further comprises a pharmaceutically acceptable food-aid additive.
본 발명에 이용될 수 있는 식품학적으로 허용가능한 식품 보조 첨가제는 포도당, 과당, 말토스, 슈크로스, 덱스트린, 시클로덱스트린과 같은 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올과 같은 천연 탄수화물, 타우마틴, 스테비아 추출물 등의 천연 향미제, 사카린, 아스파르탐 등의 합성 향미제, 착색제, 펙트산 또는 그의 염, 알긴산 또는 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산화제 등을 포함하나, 이에 제한되는 것은 아니다.Food-acceptable food supplementary additives that may be used in the present invention include sugars such as glucose, fructose, maltose, sucrose, dextrin, cyclodextrins, natural carbohydrates such as sugar alcohols such as xylitol, sorbitol, erythritol, Natural flavors such as martin and stevia extract, synthetic flavors such as saccharin and aspartame, colorants, pectic acid or its salts, alginic acid or its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin , Alcohols, carbonating agents, and the like.
본 발명의 선천 면역 증강 및 항바이러스용 건강기능식품은 분말, 과립, 정제, 캡슐, 캔디, 츄잉검, 젤리 및 음료로 이루어진 군으로부터 선택되는 형태일 수 있다.The congenital immunostimulant and antiviral health functional food of the present invention may be in a form selected from the group consisting of powder, granule, tablet, capsule, candy, chewing gum, jelly and beverage.
선천 면역 증강 및 항바이러스용 건강기능식품 중의 고련피 추출물의 함량은 식품의 형태, 풍미, 맛 등을 고려하여 적절하게 선택될 수 있으며, 예를 들어 건강기능식품 전체 중량에 대하여 0.01~30 중량%의 범위일 수 있다.The content of the ginseng extract in the healthy immuno-enhancing and antiviral health functional food may be appropriately selected in consideration of the shape, flavor, taste, etc. of the food, for example, 0.01 to 30 wt% Lt; / RTI >
본 발명의 선천 면역 증강 및 항바이러스용 건강기능식품의 형태, 조성 및 제조방법 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다. It is obvious to a person skilled in the art that the form, composition and manufacturing method of the healthy immunocomposting and antiviral health functional food of the present invention can be suitably selected from conventional techniques known in the art.
본 발명의 또 다른 일 측면은 고련피 추출물을 포함하는 선천 면역 증강 및 항바이러스용 사료 조성물에 관한 것이다.Another aspect of the present invention relates to a feed composition for congenital immunity enhancement and antiviral comprising ginseng extract.
선천 면역 증강 및 항바이러스용 사료 조성물 중의 고련피 추출물의 함량은 급여 가축의 종, 주령, 체중, 및 사육 조건 등에 따라 적절히 선택될 수 있으며, 사료 조성물 전체 중량에 대하여 0.01~95중량%, 바람직하게는 0.1~80중량%의 비율일 수 있다.The content of the ginseng extract in the composition for conferring immunity enhancement and antiviral composition can be appropriately selected according to species, age, body weight, rearing condition and the like of the feed livestock, and is preferably 0.01 to 95% by weight, May be in a proportion of 0.1 to 80% by weight.
본 발명의 선천면역 증강 및 항바이러스용 사료 조성물은 기술분야에 공지된 사료 제조방법에 따라 제조될 수 있으며, 예를 들어, 각종 사료 원료 또는 배합사료와 본 발명의 고련피 추출물을 혼합한 후, 추가적인 가공 공정, 예를 들어 펠렛 형태로의 성형 또는 과립 등의 형태로의 절단 단계 등을 더 수행함으로써 제조될 수 있다.The feed composition for congenital immunity enhancement and antiviral of the present invention can be prepared according to a feed production method known in the art. For example, after mixing various feed ingredients or compound feed with the extract of the present invention, For example, by further performing a further processing step, for example, a step in the form of pellets or a step in the form of granules or the like.
본 발명의 선천 면역 증강 및 항바이러스용 사료 조성물의 구성성분, 조성, 제조방법, 급여방법 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다.It is apparent to those skilled in the art that the composition, composition, manufacturing method, feeding method, and the like of the congenital immunostimulating and antiviral feed composition of the present invention can be appropriately selected from conventional techniques known in the art.
본 발명의 또 다른 일 측면은 고련피 추출물을, 인간을 제외한 선천 면역 증강이 필요한 동물에 투여하는 것을 포함하는 동물의 선천 면역 증강 및 항바이러스 활성 증강에 관한 것이다.Another aspect of the present invention relates to enhancing the innate immunity and antiviral activity of an animal, which comprises administering the extract to a mammal in need of innate immune enhancement other than human.
본 발명의 동물의 선천 면역 증강 및 항바이러스 활성 증강에 있어서, 고련피 추출물의 투여량, 투여경로, 투여시기 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다. It should be apparent to those skilled in the art that the dose, route of administration, administration time, etc. of the ginseng extract may be suitably selected from conventional techniques known in the art in enhancing innate immunity and antiviral activity of the animal of the present invention Do.
이와 같이 본 발명에 있어서는 대식 세포를 활성화시켜 다양한 바이러스의 증식을 억제하고, 독성이나 부작용이 거의 없는 고련피 추출물을 약학 조성물, 건강기능식품 또는 사료 조성물 등에 이용함으로써, 선천 면역 증강 및 조절, 동물의 항질병 강화 효과를 발휘할 수 있으며, 나아가 동물의 선천 면역 증강 및 항바이러스 활성 증강을 제공할 수 있다.
As described above, in the present invention, it is possible to prevent the growth of various viruses by activating macrophages, and to use the extract of Goryeo Peel, which has little toxicity or side effects, in pharmaceutical composition, health food or feed composition, Can exert an anti-disease-enhancing effect, and can further enhance the innate immunity and the antiviral activity of the animal.
이하, 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 그러나 하기 실시예는 본 발명을 예시하는 것일 뿐이며, 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are illustrative of the present invention, and the scope of the present invention is not limited to the following examples.
[[ 실시예Example ]]
1. 생약추출물의 제조1. Preparation of herbal medicine extract
생약 추출물은 10배수의 증류수를 첨가하여 105℃에서 150분간 열수 추출하고, 0.45㎛로 1차 여과한 후, 0.22㎛로 최종 여과하여 침전물을 제거하였다. 이어서, pH를 7.0으로 조정하여 1.5㎖ Ep-튜브에 1㎖씩 분주하고 -20℃에서 저장하여 모든 실험에 사용하였다.
The crude herbal extract was extracted with hot water at 105 ° C for 10 minutes, distilled water was extracted for 150 minutes, primary filtered at 0.45 μm and finally filtered at 0.22 μm to remove the precipitate. Subsequently, the pH was adjusted to 7.0 and 1 ml of each was dispensed into a 1.5 ml Ep-tube and stored at -20 캜 for all experiments.
2. 마우스 2. Mouse 대식세포주를Macrophage cell line 이용한 Used 고련피Sophisticated blood 추출물의 항바이러스 활성 실험 Experiment of antiviral activity of extract
: 다양한 바이러스, 즉 인플루엔자 바이러스(Influenza virus), 뉴캐슬병 바이러스(Newcastle disease virus), 수포성 구내염 바이러스(Vesicular stomatitis virus)에 대한 고련피 추출물의 항바이러스 활성 실험을 하기와 같이 수행하였다.
: The antiviral activity tests of various viruses such as Influenza virus, Newcastle disease virus and Vesicular stomatitis virus were carried out as follows.
(1) 항바이러스 활성 실험 방법(1) Antiviral activity test method
1) 마우스 대식세포주인 Raw 264.7을 키워 실험에 사용하였다.1) Mouse macrophage cell line Raw 264.7 was grown and used in the experiment.
2) 12-웰 TC 플레이트에 세포를 배양한 후, 1% FBS가 첨가된 DMEM에 상기에서 제조된 고련피 추출물(pH 조정)을 처리하였다.2) After culturing the cells on a 12-well TC plate, DMEM containing 1% FBS was treated with the above-prepared spinach extract (pH adjustment).
3) 음성 대조군은 1% FBS가 첨가된 DMEM만을 처리하였고, 양성 대조군(Positive control)은 Mouse IFN-B(500 units/㎖)를 처리하였다.3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control was treated with Mouse IFN-B (500 units / ml).
4) 고련피 처리 12시간 후, PR8-gfp(MOI:1), VSV-gfp(MOI:1), NDV-gfp(MOI:1)를 각각 접종하였다.(MOI: 1), VSV-gfp (MOI: 1) and NDV-gfp (MOI: 1) were inoculated 12 hours after the treatment.
5) 접종하고 2시간 후 접종액을 제거하고, PBS로 3회 세척하고, 12~24시간 후 바이러스 감염 정도를 측정하였다.
5) After 2 hours of inoculation, the inoculum was removed, washed three times with PBS, and the degree of virus infection was measured 12 to 24 hours later.
(2) 항바이러스 활성 실험결과(2) Results of antiviral activity test
1) PR8-gfp(swine influenza virus) 실험결과1) PR8-gfp (swine influenza virus) test results
도 1에 PR8-gfp에 대한 항바이러스 활성 실험결과를 나타낸다. 도 1(a)는 감염 12시간, 24시간 후의 GFP(green fluorescent protein) 형광이미지를 나타내고, 도 2(b)는 GFP 흡수도(absorbance)를 나타내며, 도 2(c)는 세포 생존율을 나타낸다.Figure 1 shows the results of the antiviral activity test for PR8-gfp. Fig. 1 (a) shows GFP (green fluorescent protein) fluorescence image at 12 hours and 24 hours after infection, Fig. 2 (b) shows GFP absorbance and Fig. 2 (c) shows cell viability.
도 1로부터, 고련피 추출물로 전처리한 결과 인플루엔자 바이러스 감염율이 현저하게 떨어졌으며, 세포 생존율도 바이러스 감염군에 비해 상승한 것을 확인할 수 있다.
From FIG. 1, it can be seen that the infection rate of influenza virus was remarkably decreased and the cell survival rate was also higher than that of the virus-infected group as a result of pretreatment with the extract of Glycyrrhizae extract.
2) VSV-gfp(Vesicular stomatitis virus) 실험결과2) Results of VSV-gfp (Vesicular stomatitis virus)
도 2에 VSV-gfp에 대한 항바이러스 활성 실험결과를 나타낸다. 도 2(a)는 감염 12시간,24시간 후의 GFP 형광이미지를 나타내고, 도 2(b)는 GFP 흡수도를 나타내고, 도 2(c)는 세포 생존율을 나타낸다.FIG. 2 shows the results of the antiviral activity test for VSV-gfp. Fig. 2 (a) shows GFP fluorescence images at 12 hours and 24 hours after infection, Fig. 2 (b) shows GFP absorption, and Fig. 2 (c) shows cell viability.
도 2으로부터 확인할 수 있는 바와 같이, 고련피 추출물로 전처리한 결과 수포성 구내염 바이러스 감염율이 현저하게 떨어졌으며, 바이러스 역가도 감소하였고, 세포 생존율도 바이러스 감염군에 비해 상승하였다.
As can be seen from FIG. 2, as a result of pretreatment with the extract of Sophora cordata, the infection rate of vesicular stomatitis virus was remarkably decreased, the virus level was decreased, and the cell survival rate was also higher than that of virus infection group.
3) NDV-gfp(newcastle disease virus) 실험결과3) NDV-gfp (newcastle disease virus)
도 3에 NDV-gfp에 대한 항바이러스 활성 실험결과를 나타낸다. 도 3(a)는 감염 12시간 후의 GFP 형광이미지를 나타내고, 도 3(b)는 GFP 흡수도를 나타내며, 도 3(c)는 세포 생존율을 나타낸다.FIG. 3 shows the results of an antiviral activity test for NDV-gfp. Fig. 3 (a) shows GFP fluorescence image after 12 hours of infection, Fig. 3 (b) shows GFP absorption, and Fig. 3 (c) shows cell viability.
도 3로부터 확인할 수 있는 바와 같이, 고련피 추출물로 전처리한 결과 뉴캐슬병 바이러스 감염율이 현저하게 떨어졌으며, 세포 생존율도 바이러스 감염군에 비해 상승하였다.
As can be seen from FIG. 3, as a result of pretreatment with the extract of Phellinus linteus, the infection rate of Newcastle disease virus was remarkably decreased and the cell survival rate was also higher than that of virus infection group.
3. 다양한 세포주를 이용한 3. Using various cell lines 고련피Sophisticated blood 추출물의 항바이러스 활성 실험 Experiment of antiviral activity of extract
: 다양한 바이러스, 즉 수포성 구내염 바이러스(VSV), 콕사키바이러스(H3), 헤르페스심플렉스바이러스(HSV), 엔테로바이러스71형(EV-71)에 대한 고련피 추출물의 항바이러스 활성 실험을 하기와 같이 수행하였다.: An antiviral activity test of various viruses, ie, vesicular stomatitis virus (VSV), coxsack virus (H3), herpes simplex virus (HSV) and enterovirus type 71 (EV-71) Respectively.
(1) 항바이러스 활성 실험 방법(1) Antiviral activity test method
1) 수포성 구내염 바이러스(Vesicular stomatitis virus), HSV(헤르페스바이러스)는 293T 세포주(human kidney cell line), H3(콕사키바이러스)와 EV-71(엔테로바이러스)는 헬라세포주(HELA cell line)을 키워 실험에 사용하였다.1) Vesicular stomatitis virus, HSV (herpes virus), H3 cell line (human kidney cell line), H3 (coxsack virus) and EV-71 (enterovirus) And used for experiments.
2) 12-웰 TC 플레이트에 세포를 배양한 후, 1% FBS가 첨가된 DMEM에 상기에서 제조된 고련피 추출물(pH 조정)을 다양한 농도로 각각 처리하였다.2) Cells were cultured on a 12-well TC plate and treated with DMEM containing 1% FBS at various concentrations, respectively.
3) 음성 대조군은 1% FBS가 첨가된 DMEM만을 처리하였고, 양성 대조군(Positive control)은 Mouse IFN-B(500 units/㎖)를 처리하였다.3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control was treated with Mouse IFN-B (500 units / ml).
4) 고련피 처리 12시간 후, VSV-gfp, H3-gfp, HSV-gfp, EV-71를 각각 접종하였다.4) After 12 hours of treatment, VSV-gfp, H3-gfp, HSV-gfp and EV-71 were inoculated respectively.
5) 접종하고 2시간 후 접종액을 제거하고, PBS로 3회 세척하고, 12~24시간 후 바이러스 감염 정도를 측정하였다.
5) After 2 hours of inoculation, the inoculum was removed, washed three times with PBS, and the degree of virus infection was measured 12 to 24 hours later.
(2) 항바이러스 활성 실험결과(2) Results of antiviral activity test
1) VSV-gfp(Vesicular stomatitis virus) 실험결과1) Results of VSV-gfp (Vesicular stomatitis virus)
도 4에 VSV-gfp에 대한 항바이러스 활성 실험결과를 나타낸다. 도 4는 감염 12시간 후의 GFP(green fluorescent protein) 형광이미지를 나타낸다. 도 4로부터, 고련피 추출물로 전처리한 결과 VSV 감염율이 현저하게 떨어진 것을 확인할 수 있다.
Figure 4 shows the results of the antiviral activity test for VSV-gfp. Figure 4 shows GFP (green fluorescent protein) fluorescence images after 12 hours of infection. From FIG. 4, it can be confirmed that the VSV infection rate was remarkably decreased as a result of pretreatment with the extract of the hardy bark.
2) H3-gfp(콕사키바이러스) 실험결과2) Experimental results of H3-gfp (coxsackievirus)
도 5에 HSV-gfp에 대한 항바이러스 활성 실험결과를 나타낸다. 도 5는 감염 12시간, 24시간 후의 GFP(green fluorescent protein) 형광이미지를 나타낸다.FIG. 5 shows the results of the antiviral activity test for HSV-gfp. Figure 5 shows GFP (green fluorescent protein) fluorescence images at 12 hours and 24 hours after infection.
도 5로부터, 고련피 추출물로 전처리한 결과 콕사키바이러스 감염율이 현저하게 떨어진 것을 확인할 수 있다.
From FIG. 5, it can be confirmed that the pre-treatment with the extract of the spinach extract significantly reduced the infection rate of the cocksuck virus.
3) HSV-gfp(헤르페스심플렉스바이러스) 실험결과3) HSV-gfp (herpes simplex virus) experiment result
도 6에 HSV-gfp에 대한 항바이러스 활성 실험결과를 나타낸다. 도 6는 감염 12시간, 24시간 후의 GFP(green fluorescent protein) 형광이미지를 나타낸다.FIG. 6 shows the results of the antiviral activity test for HSV-gfp. Figure 6 shows GFP (green fluorescent protein) fluorescence images after 12 hours and 24 hours of infection.
도 6로부터 확인할 수 있는 바와 같이, 고련피 추출물로 전처리한 결과 헤르페스 바이러스 감염율이 현저하게 떨어졌진 것을 확인할 수 있다.
As can be seen from FIG. 6, it can be confirmed that the herpes virus infection rate was remarkably decreased by pretreatment with the extract of the hardy flounder.
4) EV-71(엔테로바이러스) 실험결과4) EV-71 (Enterovirus) Experimental Results
도 7에 EV-71에 대한 항바이러스 활성 실험결과를 나타낸다. 도 7은 감염 12시간, 24시간 후의 세포주 이미지를 나타낸다.Fig. 7 shows the results of the antiviral activity test for EV-71. Figure 7 shows cell line images after 12 hours and 24 hours of infection.
도 7으로부터 확인할 수 있는 바와 같이, 고련피 추출물로 전처리한 결과 엔테로바이러스 감염율이 현저하게 떨어졌진 것을 확인할 수 있다.
As can be seen from Fig. 7, it can be confirmed that the pre-treatment with the extract of Sophorae extract significantly reduced the infection rate of enterovirus.
4. 마우스 4. Mouse 대식세포주를Macrophage cell line 이용한 Used 고련피의Bloody blood 인터페론-β 분비 유도 실험 Interferon-beta secretion induction experiment
: 고련피 추출물의 면역인자 유도효과를 확인하기 위하여 하기와 같이 실험을 수행하였다.
: Experiments were carried out as follows to confirm the induction effect of the immunopotentiating agent of the extract of Goryeo bark.
(1) 인터페론-β 분비 유도((1) induction of interferon-beta secretion ( InterferonInterferon -β -β secretionsecretion InductionInduction ) 실험방법) Experimental method
1) 마우스 대식세포주인 Raw 264.7을 키워 실험에 사용하였다.1) Mouse macrophage cell line Raw 264.7 was grown and used in the experiment.
2) 6-웰 TC 플레이트에 세포를 배양한 후, 1% FBS가 첨가된 DMEM에 상기에서 제조된 고련피 추출물(pH 조정)을 첨가하여 처리하였다.2) After culturing the cells on a 6-well TC plate, DMEM supplemented with 1% FBS was treated by adding the above-prepared spinach extract (pH adjusted).
3) 음성 대조군은 1% FBS가 첨가된 DMEM만을 처리하였고, 양성 대조군은 리포폴리사카라이드(LPS) 분말(100ng/㎖)을 처리하였다.3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control group was treated with lipopolysaccharide (LPS) powder (100ng / ml).
4) 처리 후 12시간, 24시간의 결과물에 대하여 인터페론-β의 값을 ELISA를 이용하여 측정하였다.
4) Interferon-β values were measured by ELISA for the results of 12 hours and 24 hours after the treatment.
(2) 인터페론-β 분비 유도 실험결과(2) Results of induction of interferon-beta secretion
도 8에 고련피 추출물에 의한 인터페론-β 분비 유도 실험결과를 나타낸다(NC: 음성 대조군, LPS: 양성 대조군, 고련피: 고련피 추출물 처리군). 인터페론-β는 바이러스, 암세포 등의 외부 물질에 반응하여 분비되는 사이토카인으로, 세포내 항암 및 항바이러스 작용을 일으켜 면역반응을 유도하는 물질이다.FIG. 8 shows the results of induction of interferon-beta secretion by the extract of Chinese cabbage (NC: negative control group, LPS: positive control group; Interferon-beta is a cytokine secreted in response to external substances such as viruses and cancer cells, and induces an immune response by causing an anti-cancer and anti-viral action.
도 8로부터, 고련피 추출물에 의하여 Raw cell로부터 인터페론-β 유도능이 나타나는 것을 확인할 수 있다.
From FIG. 8, it can be confirmed that the interferon-beta inducing ability from the raw cells is exhibited by the spinach extract.
5. 마우스 5. Mouse 대식세포주를Macrophage cell line 이용한 Used 고련피의Bloody blood 전염증성Proinflammatory 사이토카인 유도( Cytokine induction ( propro -- inflammatoryinflammatory CytokineCytokine Induction) 실험 Induction
: 고련피 추출물의 면역인자 유도효과를 확인하기 위하기 하기와 같이 실험을 수행하였다.
: Experiments were carried out as follows to confirm the induction effect of the immunological factor on the extract of Goryeo bark.
(1) (One) 전염증성Proinflammatory 사이토카인 유도 실험방법 Cytokine induction experiment method
1) 마우스 대식세포주인 Raw 264.7을 키워 실험에 사용하였다.1) Mouse macrophage cell line Raw 264.7 was grown and used in the experiment.
2) 6-웰 TC 플레이트에 세포를 배양한 후, 1% FBS가 첨가된 DMEM에 상기에서 제조된 고련피 추출물(pH 조정)을 첨가하여 처리하였다.2) After culturing the cells on a 6-well TC plate, DMEM supplemented with 1% FBS was treated by adding the above-prepared spinach extract (pH adjusted).
3) 음성 대조군은 1% FBS가 첨가된 DMEM만을 처리하였고, 양성 대조군은 리포폴리사카라이드(LPS) 분말(100ng/㎖)을 처리하였다.3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control group was treated with lipopolysaccharide (LPS) powder (100ng / ml).
4) 처리 후, 12시간, 24시간의 결과물에 대하여 TNF-α, IL-6의 값을 ELISA를 이용하여 측정하였다.
4) After the treatment, the values of TNF-α and IL-6 were measured by ELISA for the results of 12 hours and 24 hours.
(2) (2) 전염증성Proinflammatory 사이토카인 유도 실험결과 Cytokine induction experiment result
도 9에 고련피 추출물에 의한 전염증성 사이토카인 유도 실험결과를 나타낸다(NC: 음성 대조군, LPS: 양성 대조군, 고련피: 고련피 추출물 처리군). TNF-α는 면역 및 염증반응의 매개물질로 대식세포주를 활성화시키며 다양한 사이토카인 분비를 유도하는 물질로 B-세포를 증식시키고, IL-6는 B-세포를 활성화시켜 항체생산을 증가시켜 항원특이적 면역반응을 촉진하는 중요한 사이토카인이다.FIG. 9 shows the results of induction of proinflammatory cytokine by extracts of muscovia (NC: negative control group, LPS: positive control group; TNF-α is a mediator of immune and inflammatory responses that activates macrophages and induces a variety of cytokine secretion. B-cells proliferate and IL-6 activates B-cells to increase antibody production, It is an important cytokine that stimulates the immune response.
도 9로부터, 고련피 추출물에 의하여 Raw cell로부터 전염증성 사이토카인 유도능이 강하게 나타나는 것을 확인할 수 있다.
From FIG. 9, it can be confirmed that the proinflammatory cytokine-inducing ability from the raw cells is strongly exhibited by the extract from the spinach extract.
8. 8. 제조예Manufacturing example
(1) 주사제(1) Injection
상기 1.에서 제조된 고련피 추출물: 100 ㎎100 mg of the spinach extract prepared in the above 1.
소듐 메타비설파이트: 3.0 ㎎Sodium metabisulfite: 3.0 mg
메틸파라벤: 0.8 ㎎Methylparaben: 0.8 mg
프로필파라벤: 0.1 ㎎Propyl paraben 0.1 mg
주사용 멸균 증류수: 적량Sterile sterilized distilled water for injection:
상기 성분을 혼합하고 통상의 방법으로 최종 부피가 2 ㎖가 되도록 제조하여, 앰플에 충전하고 멸균하여 주사제를 제조하였다.
The above ingredients were mixed and made into a final volume of 2 ml by a conventional method, filled in an ampoule and sterilized to prepare an injection.
(2) 정제(2) Purification
상기 1.에서 제조된 고련피 추출물: 200 ㎎200 mg of the spinach extract prepared in the above 1.
감자 전분: 100 ㎎Potato starch: 100 mg
락토오스: 100 ㎎Lactose: 100 mg
콜로이드성 규산: 16 ㎎Colloidal silicic acid: 16 mg
스테아린산 마그네슘: 적량Magnesium stearate:
통상의 정제 제조방법에 따라 상기 성분을 혼합하고 타정하고 정제를 제조하였다.The ingredients were mixed and tableted according to a conventional tablet preparation method to prepare tablets.
(3) 캡슐제(3) Capsules
상기 1.에서 제조된 고련피 추출물: 100 ㎎100 mg of the spinach extract prepared in the above 1.
유당: 50 ㎎Lactose: 50 mg
전분: 50 ㎎Starch: 50 mg
탈크: 2 ㎎Talc: 2 mg
스테아린산 마그네슘: 적량Magnesium stearate:
통상의 캡슐 제조방법에 따라 상기 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
The above components were mixed according to a conventional capsule manufacturing method and filled in gelatin capsules to prepare capsules.
(4) 환제(4) pillars
상기 1.에서 제조된 고련피 추출물: 120 ㎎120 mg of the spinach extract prepared in the above 1.
옥수수 전분: 100 ㎎Corn starch: 100 mg
멸균 증류수: 적량Sterilized distilled water: suitable amount
상기 성분을 혼합하고, 통상의 환제 제조방법에 따라 적절한 크기를 갖는 구형으로 제환하여 환제를 제조하였다.
The above ingredients were mixed and pelletized to spheres of appropriate size according to conventional pellet manufacturing methods to produce pellets.
(5) 건강 기능 식품(5) health functional foods
1) 건강 음료1) Health drinks
올리고당(2%), 액상과당(0.5%), 설탕(2%), 식염(0.5%), 물(75%) 등의 음료 재료에 상기 1.에서 제조된 고련피 추출물을 적량 혼합하여, 살균함으로써 음료를 제조하였다.(1) to a beverage material such as an oligosaccharide (2%), a liquid fructose (0.5%), a sugar (2%), a salt (0.5%) and water (75% To prepare a beverage.
2) 기능성 식품2) Functional food
상기 1.에서 제조된 고련피 추출물을 각종 비타민 및 미네랄 함유 기능성 식품에 적량 혼합하여 고련피 추출물이 함유된 기능성 식품을 제조하였다.
The functionalized food containing the extract of the ginseng extract was prepared by mixing the ginseng extract prepared in the above 1 with various vitamins and mineral-containing functional foods in an appropriate amount.
(6) 사료 조성물(6) Feed composition
동물용 배합 사료에 상기 1.에서 제조된 고련피 추출물을 적량 혼합하여, 사료 조성물을 제조한 후, 펠렛화 및 과립화하였다.
The animal feed composition was mixed with an appropriate amount of the spinach extract prepared in the above 1. to prepare a feed composition, which was then pelletized and granulated.
상기 본 발명은 전술한 실시예 및 첨부된 도면에 의해 한정되는 것이 아니고, 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 여러 가지 치환, 변형 및 변경이 가능하다는 것이 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명백할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments or constructions. Various changes, substitutions and alterations can be made hereto without departing from the spirit and scope of the invention. It will be clear to those who have knowledge.
Claims (13)
Antiviral agent which exhibits an antiviral effect against at least one virus selected from the group consisting of Newcastle disease virus, vesicular stomatitis virus, coxsakiovirus, herpes simplex virus, and enterovirus type 71 A pharmaceutical composition.
상기 고련피 추출물은 열수 추출, 알코올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성된 것을 특징으로 하는
항바이러스용 약학 조성물.
The method according to claim 1,
Wherein the spinach extract is formed by one or more methods selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction
A pharmaceutical composition for antiviral use.
약학적으로 허용가능한 담체, 부형제 또는 희석제를 더 포함하는 것을 특징으로 하는
항바이러스용 약학 조성물.
The method according to claim 1,
Characterized in that it further comprises a pharmaceutically acceptable carrier, excipient or diluent
A pharmaceutical composition for antiviral use.
상기 약학적 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁액, 에멀젼, 시럽제, 에어로졸, 외용제, 좌제 및 주사제로 이루어진 군으로부터 선택되는 형태인 것을 특징으로 하는
항바이러스용 약학 조성물.
The method according to claim 1,
Wherein the pharmaceutical composition is in a form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and injections
A pharmaceutical composition for antiviral use.
Antiviral agent which exhibits an antiviral effect against at least one virus selected from the group consisting of Newcastle disease virus, vesicular stomatitis virus, coxsakiovirus, herpes simplex virus, and enterovirus type 71 Health functional foods.
상기 고련피 추출물은 열수 추출, 알코올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성된 것을 특징으로 하는
항바이러스용 건강기능식품.
6. The method of claim 5,
Wherein the spinach extract is formed by one or more methods selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction
Antiviral Health Foods.
식품학적으로 허용가능한 식품 보조 첨가제를 더 포함하는 것을 특징으로 하는
항바이러스용 건강기능식품.
6. The method of claim 5,
Characterized in that it further comprises a food-acceptable food-aid additive
Antiviral Health Foods.
상기 건강기능식품은 분말, 과립, 정제, 캡슐, 캔디, 츄잉검, 젤리 및 음료로 이루어진 군으로부터 선택되는 형태인 것을 특징으로 하는
항바이러스용 건강기능식품.
6. The method of claim 5,
Wherein the health functional food is a form selected from the group consisting of powder, granule, tablet, capsule, candy, chewing gum, jelly and beverage
Antiviral Health Foods.
Antiviral agent which exhibits an antiviral effect against at least one virus selected from the group consisting of Newcastle disease virus, vesicular stomatitis virus, coxsakiovirus, herpes simplex virus, and enterovirus type 71 Feed composition.
상기 고련피 추출물은 열수 추출, 알코올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성된 것을 특징으로 하는
항바이러스용 사료 조성물.
10. The method of claim 9,
Wherein the spinach extract is formed by one or more methods selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction
An antiviral feed composition.
The present invention also relates to a method for treating at least one virus selected from the group consisting of Newcastle Disease virus, vesicular stomatitis virus, cocksuck virus, herpes simplex virus, and enterovirus type 71, A method for enhancing an antiviral activity of an animal exhibiting an antiviral effect.
상기 고련피 추출물은 열수 추출, 알코올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성된 것을 특징으로 하는
항바이러스 활성 증강 방법.12. The method of claim 11,
Wherein the spinach extract is formed by one or more methods selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction
A method for enhancing antiviral activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130052402A KR101715646B1 (en) | 2013-05-09 | 2013-05-09 | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130052402A KR101715646B1 (en) | 2013-05-09 | 2013-05-09 | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140132975A KR20140132975A (en) | 2014-11-19 |
| KR101715646B1 true KR101715646B1 (en) | 2017-03-14 |
Family
ID=52453751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130052402A KR101715646B1 (en) | 2013-05-09 | 2013-05-09 | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101715646B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019168222A1 (en) * | 2018-02-28 | 2019-09-06 | 주식회사 제넨셀 | Culture medium composition for culturing of anti-cancer activated lymphocytes derived from peripheral blood mononuclear cells and method for culturing anti-cancer activated lymphocytes using same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007254319A (en) | 2006-03-22 | 2007-10-04 | Yanbaru Green Health:Kk | Influenza-preventing/treating agent |
| US20110111064A1 (en) * | 2008-07-09 | 2011-05-12 | The Institute Of Biological | Anti-Influenza Virus Agent, Anti-RS Virus Agent, and Anti-Immunodeficiency Virus Agent |
-
2013
- 2013-05-09 KR KR1020130052402A patent/KR101715646B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007254319A (en) | 2006-03-22 | 2007-10-04 | Yanbaru Green Health:Kk | Influenza-preventing/treating agent |
| US20110111064A1 (en) * | 2008-07-09 | 2011-05-12 | The Institute Of Biological | Anti-Influenza Virus Agent, Anti-RS Virus Agent, and Anti-Immunodeficiency Virus Agent |
Non-Patent Citations (2)
| Title |
|---|
| BUENO, CARLOS A. et al., ‘A natural tetranortriterpenoid with immunomodulating properties as a potential anti-HSV agent’, Virus Research Vol.141, pp.47-54, 2009* |
| PETRERA, ERINA et al., ‘Therapeutic Effect of Meliacine, An Antiviral Derived from Melia azedarach L., in Mice Genital Herpetic Infection’, Phytotherapy Research. Vol.23, pp.1771-1777, 2009* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140132975A (en) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101780975B1 (en) | Composition for enhancing innate immunity and antivirus comprising Pini Pollen extract as effective component | |
| KR101951003B1 (en) | Composition for enhancing innate immunity and antivirus comprising Echinopsis Radix extract as effective component | |
| KR101669988B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Phellodendri Cortex | |
| KR101951010B1 (en) | Composition for enhancing innate immunity and antivirus comprising Isatidis Folium extract as effective component | |
| KR101770573B1 (en) | Composition for enhancing innate immunity and antivirus comprising Schizonepetae Spica extract as effective component | |
| KR101930778B1 (en) | Composition for antivirus comprising Ulmi Cortex extract as effective component | |
| KR101725938B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Coptis japonica (Thunb.) Makino | |
| KR101874465B1 (en) | Composition for enhancing innate immunity and antivirus comprising Eupatorii Herba extract as effective component | |
| KR101762606B1 (en) | Composition for enhancing innate immunity and antivirus comprising Foeniculi Fructus extract as effective component | |
| KR101782847B1 (en) | Composition for enhancing innate immunity and antivirus comprising Hoveniae Semen Cum Fructus extract as effective component | |
| KR101725944B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Cimicifuga heracleifolia Komarow | |
| KR101837445B1 (en) | Composition for enhancing innate immunity and antivirus comprising Dianthi Herba extract as effective component | |
| KR101951008B1 (en) | Composition for enhancing innate immunity and antivirus comprising Psoraleae Semen extract as effective component | |
| KR101762608B1 (en) | Composition for enhancing innate immunity and antivirus comprising Hoveniae Semen Cum Fructus extract as effective component | |
| KR101770572B1 (en) | Composition for enhancing innate immunity and antivirus comprising Mori Ramulus or Mori Radicis Cortex extract as effective component | |
| KR101837448B1 (en) | Composition for enhancing innate immunity and antivirus comprising Piperis Longi Fructus extract as effective component | |
| KR101715646B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Meliae Cortex | |
| KR20160112831A (en) | Composition for enhancing innate immunity and antivirus comprising Chelidonii herba extract as effective component | |
| KR101677119B1 (en) | INNATE IMMUNE ENHANCING AND ANTIVIRAL COMPOSITION COMPRISING EXTRACT OF Angelicae Tenuissimae Radix | |
| KR101791036B1 (en) | Composition for enhancing innate immunity and antivirus comprising Melandrii Herba extract as effective component | |
| KR20160118740A (en) | Composition for enhancing innate immunity and antivirus comprising Puerariae Flos extract as effective component | |
| KR20160112840A (en) | Composition for antivirus comprising Trichosanthis Radix extract as effective component | |
| KR101967921B1 (en) | Composition for enhancing innate immunity and antivirus comprising Drynaria Rhizome extract as effective component | |
| KR20160104979A (en) | Composition for enhancing innate immunity and antivirus comprising Eriocauli Herba extract as effective component | |
| KR101800443B1 (en) | Composition for enhancing innate immunity and antivirus comprising Asteris Radix extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20200309 Year of fee payment: 4 |